Here comes a third desmoid tumour player
Parabilis’s zolucatetide bids to be third to a rather small market.
The Bristol/HengRui guessing game begins
What could be the four HengRui assets picked up by Bristol?
Cytospire’s backers buy in as Pfizer exits
No sooner does one gammadelta-focused biotech die than another takes its place.
Merck quietly ditches its sac-tmt copy
MK-6837 has been discontinued, the company discloses.
Astra’s Datroway biomarker gives and it takes away
The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
Gilead edges further away from Arcus
The disclosure comes as another of Arcus's TIGIT trials flops.
